<DOC>
	<DOCNO>NCT01802879</DOCNO>
	<brief_summary>The study allow continue use single agent panobinostat patient single agent panobinostat treatment Novartis-sponsored study meet endpoint benefiting treatment judge investigator .</brief_summary>
	<brief_title>Study Allow Access Single Agent Panobinostat Patients Who Are s.a. Panobinostat Treatment Novartis-sponsored Study Are Benefiting From Treatment Judged Investigator</brief_title>
	<detailed_description>This multi-center open label study provide continue use single agent oral panobinostat patient currently treat Novartis-sponsored study ( parent study ) meet endpoint benefit continuation treatment single-agent panobinostat judge investigator . Patients multiple parent study transfer protocol continue receive single agent panobinostat last assign dose regimen parent protocol . There screen period , patient visit study center least quarterly basis . During visit limit information study treatment occurrence SAEs collect clinical database . SAEs report Novartis safety database.Other assessment possibly frequent visit occur per standard care site . Patients continue treatment longer benefit panobinostat treatment develop unacceptable toxicity , withdraw consent , non-compliant protocol , investigator feel longer best interest continue , patient dy , administrative reason . An end treatment visit safety follow-up 30 day last dose perform . The study expect remain open 5 year time enrol patient longer need treatment panobinostat , whichever come early .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>patient currently enrol Novartis sponsor study , meet endpoint receive single agent oral panobinostat patient currently benefit treatment single agent oral panobinostat determine guideline parent protocol accord investigator 's clinical judgment . patient demonstated compliance patient give write informed consent . patient permanently discontinue single agent oral panobinostat study treatment parent study patient participate Novartis sponsor combincation trial panobinostat dispense combination another study medication still receive combination therapy patient pregnant nursing time entry woman childbearing potential male patient sexual partner childbearing potential unwilling use highly effective method contraception dose specify duration stop study treatment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hematologic Neoplasms , LBH589 ,</keyword>
	<keyword>Panobinostat ,</keyword>
</DOC>